Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT

Artigo Acesso aberto Revisado por pares

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT

2024; American Diabetes Association; Volume: 47; Issue: 8 Linguagem: Inglês

10.2337/dc24-0764

ISSN

1935-5548

Autores

Ildiko Lingvay, John Deanfield, Steven E. Kahn, Peter Weeke, Hermann Toplak, Benjamin M. Scirica, Lars Rydén, Naveen Rathor, Jorge Plutzky, Cristóbal Morales, A. Michael Lincoff, Michael Lehrke, Ole K. Jeppesen, Grzegorz Gajos, Helen M. Colhoun, Bertrand Cariou, Donna H. Ryan,

Tópico(s)

Cardiovascular Function and Risk Factors

Resumo

To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT